[Jiechuang Intelligent Technology Co., Ltd. 2025 Interim Positive Profit Alert Announcement](index=1&type=section&id=%E6%9D%B0%E5%88%9B%E6%99%BA%E8%83%BD%E7%A7%91%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%A2%9E%E5%85%AC%E5%91%8A) The company announces a significant turnaround to profitability for H1 2025, driven by business growth and cost control [Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company expects a turnaround to profitability in H1 2025, with net profit forecasted between RMB 15-20 million H1 2025 Profit Forecast | Item | Current Period | Same Period Last Year | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Profit: RMB 15.00 - 20.00 million | Loss: RMB -33.09 million | | YoY Growth | 152.62% - 167.73% | - | | **Net Profit After Non-recurring Items** | Profit: RMB 10.00 - 15.00 million | Loss: RMB -35.50 million | | YoY Growth | 128.17% - 142.26% | - | | **Basic Earnings Per Share (EPS)** | Profit: RMB 0.10 - 0.13 / share | Loss: RMB -0.22 / share | [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The profit turnaround is attributed to strong main business growth, a shift to high-margin models, and effective cost controls [Impact of Main Business](index=1&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%BD%B1%E5%93%8D) Performance was driven by rapid growth in AI-related businesses, a shift to high-margin models, and successful cost optimization - The AI strategy upgrade drove rapid growth in **"AI + Cloud Computing"** due to strong demand for AI all-in-one machines and in **"AI + Security"** due to scaled procurement and new product launches[6](index=6&type=chunk) - An accelerated shift to high-margin product and operational business models led to a **significant year-over-year increase in gross profit**[6](index=6&type=chunk) - The company achieved effective cost reduction by optimizing personnel and expense structures, resulting in a **decrease in overall expenses YoY** despite new share-based payment costs[7](index=7&type=chunk) [Impact of Non-recurring Gains and Losses](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E5%BD%B1%E5%93%8D) Non-recurring items, primarily investment income, are expected to contribute approximately RMB 5 million to profit - The estimated impact of non-recurring gains and losses on profit for the period is approximately **RMB 5.00 million**, mainly from investment income[8](index=8&type=chunk) [Other Relevant Explanations](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company clarifies that this forecast is preliminary and unaudited, with final data to be released in the interim report - This earnings forecast is based on preliminary calculations by the finance department and **has not been audited** by an accounting firm[5](index=5&type=chunk)[9](index=9&type=chunk) - Final financial data will be disclosed in the company's 2025 semi-annual report; investors are advised to be aware of investment risks[9](index=9&type=chunk)

Group 1 - Jichuan Pharmaceutical's "Children's Constipation Granules" has received a registration application acceptance notice, marking it as the first innovative traditional Chinese medicine specifically for treating pediatric constipation [1] - The product is expected to be the first Class 1 pediatric-specific drug for constipation following the release of the clinical research guidelines in 2024 [1] Group 2 - Innovent Biologics' drug Daberat® has become the first KRAS G12C inhibitor approved in Macau, providing a new targeted therapy for patients with advanced non-small cell lung cancer [2] - In a Phase II clinical trial, Daberat® demonstrated an objective response rate (ORR) of 49.1%, a median progression-free survival (PFS) of 9.7 months, and a 12-month overall survival (OS) rate of 54.4% [2] Group 3 - Sinovac Biotech's special shareholders meeting approved the election of 10 new directors proposed by SAIF Partners, who committed to support the company's dividend distribution plan [3] - The new board members aim to work closely with management to restore trading of the company's common stock and enhance long-term shareholder value [3] Group 4 - Ganli Pharmaceutical expects a net profit increase of 100.73% to 114.12% for the first half of 2025, with projected profits between 600 million to 640 million yuan [4] - The company achieved market share expansion through two rounds of insulin procurement, with a significant 32.6% increase in agreement volume during the 2024 procurement [4] Group 5 - Ascentage Pharma's new Bcl-2 inhibitor, Lisangtuo® (APG-2575), has been conditionally approved for marketing in China, becoming the first Bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma [5] - This marks Ascentage Pharma's second innovative drug to be approved and enter the commercialization stage [5] Group 6 - United Biomedical's UBT37034 injection has received FDA approval for clinical trials, showing significant weight reduction effects when combined with GLP-1 analogs in preclinical studies [6] - The combination therapy demonstrated superior weight loss effects compared to other investigational drugs [6]

证券代码：301248 证券简称：杰创智能 公告编号：2025-054 杰创智能科技股份有限公司 龙飞先生自 2025 年 1 月 7 日至 2025 年 7 月 9 日之间，累计增持公司股票 372,000 股，占公司总股本的 0.2428%，累计增持金额 700.08 万元，其中本次增 持计划期间（2025 年 1 月 9 日至 2025 年 7 月 9 日）累计增持 237,800 股，占公 司总股本的比例为 0.1552%，累计增持金额 500.10 万元。 公司已收到孙超先生、龙飞先生出具的《关于股份增持计划实施完成的告知 函》，现将相关情况公告如下： 一、增持计划的基本情况 1、增持主体：本次计划增持主体为公司控股股东、实际控制人之一、董事 长孙超先生及其控制主体，公司控股股东、实际控制人之一、董事、总裁龙飞先 生。实施本次增持计划前的持股情况如下： 关于控股股东增持计划实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 杰创智能科技股份有限公司（以下简称"公司"）于 2025 年 1 月 9 日披露 了《关于控股股东增 ...

Core Viewpoint - Jiechuan Intelligent (301248) has signed a strategic cooperation agreement with Hangzhou Xinfengwei Technology to collaborate on AI digital ecosystem development and urban digital transformation, focusing on deploying secure and reliable computing infrastructure and intelligent applications [1] Group 1 - The partnership aims to establish a joint venture that will focus on the development of computing cluster construction and intelligent cloud service business [1] - The collaboration is expected to continuously expand the scale of intelligent cloud business [1] - Hangzhou Xinfengwei Technology is a joint venture of Alibaba and the world's first co-creation company of DingTalk [1]

二、本次募集资金专户开立情况及三方监管协议签署情况 2025年6月6日公司召开第四届董事会第十二次会议、第四届监事会第九次会 议审议并通过《关于部分募投项目结项、变更并将节余募集资金及剩余超募资金 投入新项目的议案》，同意公司结项"智慧城市平台升级及产业化项目"，调整 "智慧安全产品升级及产业化项目"、"杰创研究院建设项目"投资总金额，并 将结项、调整后的结余资金合计10,821.10万元以及剩余超募资金5,267.61万元（合 计16,088.71万元）用于投资新项目"智算云服务建设及运营项目"，并授权公司 管理层负责开立募集资金专户、签署募集资金三方监管协议以及办理其他相关事 宜。具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）披露的《关于部分募投项目结项、变更并将节余募集资金 及剩余超募资金投入新项目的公告》（公告编号：2025-047）。 近日，公司已在广发银行股份有限公司广州分行开立"智算云服务建设及运 营项目"专户，为规范公司募集资金管理，保护中小投资者的权益，根据《上市 公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳证券交 ...

证券代码：301248 证券简称：杰创智能 公告编号：2025-052 杰创智能科技股份有限公司 2025年第二次临时股东会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本次股东会召开前新增了临时提案《关于部分募投项目结项、变更并将节余募 集资金及剩余超募资金投入新项目的议案》。 一、会议召开和出席情况 召开方式：现场投票和网络投票相结合的方式。 召集人：公司董事会。 主持人：董事长孙超先生。 公司分别于2025年5月30日、2025年6月7日在中国证监会指定的信息披露网站 （巨潮资讯网http://www.cninfo.com.cn）上披露了《关于召开2025年第二次临时股 东会的通知》（公告编号：2025-044）、《关于2025年第二次临时股东会延期暨增加 临时提案的公告》（公告编号：2025-049）。本次会议的召集、召开符合《中华人民 共和国公司法》《上市公司股东会规则》等有关法律法规的规定及《公司章程》的规 定。 （一）召开情况 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于杰创智能科技股份有限公司 2025 年第二次临时股东会的 法律意见书 国枫律股字[2025] A0323 号 致：杰创智能科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第二次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《杰创智能科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法 ...

Group 1 - Dongfang Shenghong's controlling shareholder plans to increase its stake by 500 million to 1 billion yuan within six months [1] - Aiwei Electronics is set to mass-produce a low-power high-voltage piezoelectric micro-pump liquid cooling product, marking a breakthrough in domestic chip technology [1] - *ST Jiuyou received a decision from the Shanghai Stock Exchange to terminate its stock listing, which will transition to the national SME share transfer system [2] Group 2 - Hangzhou Garden plans to invest up to 450 million yuan to build a smart ecological design R&D headquarters [2] - Tiancheng Self-Control intends to invest 20 million yuan to establish a subsidiary [3] - Leidi Ke is acquiring a 30% stake in a partnership fund for 40 million yuan, indirectly holding 20% equity in Beifang Machinery [5] Group 3 - Jiangbolong's subsidiary signed a memorandum of cooperation with Sandisk to develop customized UFS products for the mobile and IoT markets [6] - Tongda Co. announced plans for its directors and executives to reduce their holdings by a total of 0.029% [7] - Yinlun Co.'s subsidiary completed the counseling acceptance for its public offering and listing on the Beijing Stock Exchange [8] Group 4 - Hongli Zhihui's controlling shareholder obtained a special loan of up to 45 million yuan for stock buyback [9] - Fengshan Group's shareholders plan to reduce their holdings by a total of 983,000 shares [11] - Kuai Ke Electronics' shareholder plans to reduce their holdings by up to 2% [13] Group 5 - Zhongdian Xinlong's director plans to reduce their holdings by up to 0.81% [15] - Maihe Co.'s shareholder intends to reduce their holdings by up to 1.5% [17] - Yuandao Communication's shareholder plans to reduce their holdings by up to 1.01% [19] Group 6 - Muyuan Co. submitted its H-share issuance application to the China Securities Regulatory Commission [21] - Jiechuang Intelligent won a police equipment procurement project worth 11.2362 million yuan [21] - Chongqing Steel signed an asset transfer contract worth 1.081 billion yuan with the Heavy Steel Group [22]

Core Viewpoint - The company, Jiechuang Intelligent (301248), has won a procurement project for police equipment from a provincial public security bureau, with a contract value of RMB 11.2362 million [1] Group 1: Project Details - The project involves the procurement of handheld electromagnetic net capture devices, which are intended for security and emergency response in key locations and situations [1] - The product utilizes electromagnetic launch technology, offering advantages such as non-contact capture and intelligent recognition [1] Group 2: Future Developments - The company is accelerating the innovation and research of multi-launch electromagnetic net capture devices, security robots, and security drones to expand applications in public security, firefighting, and emergency response [1] - The company aims to deepen AI empowerment in security, expand market share, and drive performance growth in the future [1]

杰创智能科技股份有限公司（以下简称"公司"）中标某省公安厅警械装备 采购项目，中标金额为人民币 1,123.6225 万元。现根据公司《自愿性信息披露 管理制度》的相关规定，将有关信息公告如下： 证券代码：301248 证券简称：杰创智能 公告编号：2025-051 杰创智能科技股份有限公司 关于项目中标的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、风险提示 特此公告。 一、中标项目情况 杰创智能科技股份有限公司 二、中标项目对公司的影响 董事会 本次中标意味着公司的产品化升级战略取得持续进展，标志着公司 AI+新质 安全产品的规模化落地。该产品采用电磁弹射技术，具备无接触抓捕、智能识别 等优势，主要应用于重点场所安保防控、危险目标抓捕控制、突发事件应急处置 等场景，能够提升公共安全事件处置效率，降低人民群众和警务人员安全风险， 正加速向全国推广落地。目前公司正加快多连发电磁网捕器、安保机器狗、安保 无人机等具身智能产品的创新研发，拓展公安、消防、应急等应用场景。未来， 公司将持续深化 AI 赋能安全，扩大市场份额，推动业绩增长，以 ...